A paper coronavirus test could effectively replace more expensive, less accurate antigen tests in India


India has the world's second highest coronavirus case count and appears to be on pace to overtake the United States in the next few weeks. To counter the rising number of infections, the country has scaled up testing. It hasn't been an easy process, but now 1 million samples are tested daily across more than 1,200 labs, and a newly-developed paper-based test that uses CRISPR gene-editing tools to detect the virus could become the third type of test — after PCR and antigen — to bolster the national diagnostic effort, BBC News reports.
The new test, called Feluda after a famous fictional Indian detective, employs a nasal swab and can return results in less than hour, making it faster than PCR tests. Its 96 percent sensitivity and 98 percent specificity rate means it will likely be more accurate than the rapid antigen tests. It would also reportedly be more affordable than both. In short, there's hope it could be the best of the both worlds. "The new test has the reliability of the PCR test, is quicker and can be done in smaller laboratories which don't have sophisticated machines," said Dr. Anurag Agarwal, the director of the Delhi-based CSIR-Institute of Genomics and Integrative Biology, where Feluda was developed.
Dr. Stephen Kissler, a research fellow at Harvard Medical School, told BBC that if Feluda's "efficacy is demonstrated, it can have benefits that ripple around the world." The next step for the development team is to build a prototype of a similar test that can be done from home. Read more at BBC.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The mounting tensions between Thailand and Cambodia
The Explainer Long-running border disputes are at a decade high, as protesters in Thailand demand the prime minister's resignation
-
The unravelling of 'trolls' paradise' Tattle Life
In the Spotlight Unmasking of founder sends shockwaves through toxic gossip forum
-
Codeword: June 30, 2025
The Week's daily codeword puzzle
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia